News | March 31, 2008

Study Finds Support for PCI in Unprotected Left Main Disease

April 1, 2008 - Percutaneous coronary intervention (PCI) may be a reasonable alternative to bypass surgery in patients with blockages in the left main coronary artery, according to a study that found no significant difference in rates of survival when stents and bypass surgery were used to restore blood flow through this critically important artery.

Patients who were treated with stenting were more likely to need a repeat procedure to keep the artery open, however.

The findings come from the Revascularization for Unprotected Left MAIN Coronary Artery Stenosis: COMparison of Percutaneous Coronary Angioplasty Versus Surgical REvascularization (MAIN- COMPARE) study, which drew its data from a large multicenter data registry in Korea, where left-main stenting is far more common than in the U.S.

The study was reported yesterday in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC). This study will simultaneously publish in The New England Journal of Medicine.

The left-main coronary artery supplies blood to approximately 75 percent of the left ventricle. When a blockage is located in the left main coronary artery, coronary artery bypass surgery (CABG) is usually considered the safest procedure, unless the patient is protected by an existing bypass graft that routes blood to another major coronary artery supplying the left side of the heart.

The new study suggests it is worth considering stent implantation even if the left main coronary artery is unprotected by a prior bypass graft. "Because the recommendation for surgery for left main disease is based mostly on survival benefit, the lack of a statistically significant difference in mortality may support PCI as an alternative option to bypass surgery," said Seung-Jung Park, M.D., Ph.D., director of interventional cardiology at Asan Medical Center, Seoul, Korea. "It is also worth noting that most of patients treated with drug-eluting stents who need target vessel revascularization can be treated with subsequent PCI, without significant increase of death or serious complications."

For the study, Dr. Park and his colleagues analyzed data from 2,240 patients with unprotected left main coronary artery disease treated at 12 medical centers in Korea. Of these, 318 were treated with bare-metal stents, 784 were treated with drug-eluting stents, and 1,138 underwent bypass surgery. During three years of follow-up, patients treated with bare-metal stents were nearly 11 times as likely to need a repeat procedure to reopen the target vessel when compared to those who underwent bypass surgery.

However, the rates of death (hazard ratio: 1.04) and the combined rates of death, heart attack and stroke (hazard ratio: 0.86) were similar in the two groups. Patients treated with drug-eluting stents were nearly six times as likely to need a repeat procedure during three years of follow-up, but the rates of death (hazard ratio 1.36) and the combined rates of death, heart attack and stroke (hazard ratio: 1.40) were statistically similar, although there was a trend toward higher event rates with drug-eluting stents.

The next step is to test the study's findings in a more rigorous clinical trial, Dr. Park said. "Based on these observations, a randomized trial comparing PCI with drug-eluting stents and CABG is warranted in patients with unprotected left main disease who are candidates for revascularization," he said. "However, unprotected left main stenting should not be attempted in clinical practice before the physician has achieved specialized experiences."

For more information: www.scai-acci2.org


Related Content

News | Stents

Oct. 16, 2024 — Sahajanand Medical Technologies (SMT) recently announced the publication of the COMPARE 60/80 HBR trial ...

Home October 16, 2024
Home
News | Stents

June 12, 2024 — Royal Philips, a global leader in health technology, announced the first implant of the Duo Venous Stent ...

Home June 12, 2024
Home
News | Stents

June 4, 2024 — A patient at HonorHealth Research Institute is one of the nation’s first — and the first in Arizona and ...

Home June 04, 2024
Home
News | Stents

April 17, 2024 — Getinge and Cook Medical announced an exclusive sales and distribution agreement for the iCast covered ...

Home April 17, 2024
Home
News | Stents

March 8, 2024 — Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact ...

Home March 08, 2024
Home
News | Stents

January 19, 2024 — W. L. Gore & Associates, Inc. announced that the first patients have been enrolled in the Gore VBX ...

Home January 19, 2024
Home
News | Stents

November 29, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home November 29, 2023
Home
News | Stents

July 27, 2023 — Abiomed is recalling the Impella Intravascular Left Sided Blood Pumps because the pump’s Instructions ...

Home July 27, 2023
Home
News | Stents

June 13, 2023 — W. L. Gore & Associates (Gore) announced the initiation of the Gore VBX FORWARD Clinical Study ...

Home June 13, 2023
Home
News | Stents

March 5, 2023 — In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents ...

Home March 05, 2023
Home
Subscribe Now